Limb Girdle Muscular Dystrophy Pipeline Assessment, 2024: FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, and Growth Prospects | Catabasis Pharmaceuticals, Sarepta Therapeutics, Strykagen, Sarepta Therapeutics, aTyr Ph

Limb Girdle Muscular Dystrophy pipeline constitutes 20+ key companies continuously working towards developing 25+ Limb Girdle Muscular Dystrophy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Limb Girdle Muscular Dystrophy Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Limb Girdle Muscular Dystrophy Market.

The Limb Girdle Muscular Dystrophy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Limb Girdle Muscular Dystrophy Pipeline Report: https://www.delveinsight.com/report-store/limb-girdle-muscular-dystrophy-lgmd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Limb Girdle Muscular Dystrophy treatment therapies with a considerable amount of success over the years. Limb Girdle Muscular Dystrophy Key players such as - Catabasis Pharmaceuticals, Sarepta Therapeutics, Strykagen, Sarepta Therapeutics, aTyr Pharma, ML Bio Solutions, and others, are developing therapies for the Limb Girdle Muscular Dystrophy treatment
• Limb Girdle Muscular Dystrophy Emerging therapies such as - CAT-1004, SRP-9005, Stryka 516s, MYO 102, SRP-9003, ATYR1940, BBP-418, and others are expected to have a significant impact on the Limb Girdle Muscular Dystrophy market in the coming years.
• ML Bio Solutions in February 2021, initiated an Open Label Phase 2 Study of BBP-418 in Patients With Limb Girdle Muscular Dystrophy Type 2I (MLB-01-003). BBP-418 is being developed for the treatment of patients with Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I).
• In January 2024, Sarepta Therapeutics has initiated the screening process for its Phase III EMERGENE clinical trial (Study SRP-9003-301) for the investigational gene therapy SRP-9003 (bidridistrogene xeboparvovec) intended to treat limb-girdle muscular dystrophy Type 2E (LGMD2E/R4), also known as beta sarcoglycanopathy. This multinational trial, conducted in an open-label format, aims to evaluate SRP-9003 in 15 participants.
• In August 2023, Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy firm fully owned and operated as a subsidiary of Bayer AG, disclosed today that the initial patient has received a dose in the Phase 1 / Phase 2 LION-CS101 clinical trial targeting patients with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). AB-1003 (also referred to as LION-101) is an innovative investigational therapy aimed at replacing the FKRP gene.

Limb Girdle Muscular Dystrophy Overview
Limb-girdle muscular dystrophy (LGMD) refers to a group of inherited muscle disorders characterized by progressive weakness and wasting of the muscles around the hips and shoulders, known as the limb-girdle muscles. There are several subtypes of LGMD, each caused by mutations in different genes that play a role in muscle structure and function.

Get a Free Sample PDF Report to know more about Limb Girdle Muscular Dystrophy Pipeline Assessment- https://www.delveinsight.com/sample-request/limb-girdle-muscular-dystrophy-lgmd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Limb Girdle Muscular Dystrophy Pipeline Therapeutics Assessment
• Limb Girdle Muscular Dystrophy Assessment by Product Type
• Limb Girdle Muscular Dystrophy By Stage and Product Type
• Limb Girdle Muscular Dystrophy Assessment by Route of Administration
• Limb Girdle Muscular Dystrophy By Stage and Route of Administration
• Limb Girdle Muscular Dystrophy Assessment by Molecule Type
• Limb Girdle Muscular Dystrophy by Stage and Molecule Type

DelveInsight's Limb Girdle Muscular Dystrophy Report covers around 25+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Download Sample PDF Report to know more about Limb Girdle Muscular Dystrophy drugs and therapies- https://www.delveinsight.com/sample-request/limb-girdle-muscular-dystrophy-lgmd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Limb Girdle Muscular Dystrophy Drugs Under Different Phases of Clinical Development Include:
• CAT-1004: Catabasis Pharmaceuticals
• SRP-9005: Sarepta Therapeutics
• Stryka 516s: Strykagen
• MYO 102: Sarepta Therapeutics
• SRP-9003: Sarepta Therapeutics
• ATYR1940: aTyr Pharma
• BBP-418: ML Bio Solutions

Limb Girdle Muscular Dystrophy Pipeline Analysis:
The Limb Girdle Muscular Dystrophy pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the Limb Girdle Muscular Dystrophy treatment with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Limb Girdle Muscular Dystrophy Treatment.
• Limb Girdle Muscular Dystrophy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Limb Girdle Muscular Dystrophy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Limb Girdle Muscular Dystrophy market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Limb Girdle Muscular Dystrophy product details are provided in the report. Download the Limb Girdle Muscular Dystrophy pipeline report to learn more about the emerging Limb Girdle Muscular Dystrophy therapies at:
https://www.delveinsight.com/sample-request/limb-girdle-muscular-dystrophy-lgmd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Limb Girdle Muscular Dystrophy Pipeline Market Drivers
• Increasing awareness about available treatment options
• A better understanding of disease pathogenesis

Limb Girdle Muscular Dystrophy Pipeline Market Barriers
• No cure exists for any form of Limb Girdle Muscular Dystrophy
• Lack of proper Genetic Counselling, which is to be given to individuals and their families.

Scope of Limb Girdle Muscular Dystrophy Pipeline Drug Insight
• Coverage: Global
• Key Limb Girdle Muscular Dystrophy Companies: Catabasis Pharmaceuticals, Sarepta Therapeutics, Strykagen, Sarepta Therapeutics, aTyr Pharma, ML Bio Solutions, and others
• Key Limb Girdle Muscular Dystrophy Therapies: CAT-1004, SRP-9005, Stryka 516s, MYO 102, SRP-9003, ATYR1940, BBP-418, and others
• Limb Girdle Muscular Dystrophy Therapeutic Assessment: Limb Girdle Muscular Dystrophy current marketed and Limb Girdle Muscular Dystrophy emerging therapies
• Limb Girdle Muscular Dystrophy Market Dynamics: Limb Girdle Muscular Dystrophy market drivers and Limb Girdle Muscular Dystrophy market barriers

Request for Sample PDF Report for Limb Girdle Muscular Dystrophy Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/limb-girdle-muscular-dystrophy-lgmd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1 Limb Girdle Muscular Dystrophy Report Introduction
2 Limb Girdle Muscular Dystrophy Executive Summary
3 Limb Girdle Muscular Dystrophy Overview
4 Limb Girdle Muscular Dystrophy- Analytical Perspective In-depth Commercial Assessment
5 Limb Girdle Muscular Dystrophy Pipeline Therapeutics
6 Limb Girdle Muscular Dystrophy Late Stage Products (Phase II/III)
7 Limb Girdle Muscular Dystrophy Mid Stage Products (Phase II)
8 Limb Girdle Muscular Dystrophy Early Stage Products (Phase I)
9 Limb Girdle Muscular Dystrophy Preclinical Stage Products
10 Limb Girdle Muscular Dystrophy Therapeutics Assessment
11 Limb Girdle Muscular Dystrophy Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Limb Girdle Muscular Dystrophy Key Companies
14 Limb Girdle Muscular Dystrophy Key Products
15 Limb Girdle Muscular Dystrophy Unmet Needs
16 Limb Girdle Muscular Dystrophy Market Drivers and Barriers
17 Limb Girdle Muscular Dystrophy Future Perspectives and Conclusion
18 Limb Girdle Muscular Dystrophy Analyst Views
19 Appendix
20 About DelveInsight

Related Reports:

Limb Girdle Muscular Dystrophy Market
https://www.delveinsight.com/report-store/limb-girdle-muscular-dystrophy-lgmd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Limb Girdle Muscular Dystrophy-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Limb Girdle Muscular Dystrophy Epidemiology https://www.delveinsight.com/report-store/limb-girdle-muscular-dystrophy-lgmd-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Limb Girdle Muscular Dystrophy Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:

Hypertrophic Scar Market
https://www.delveinsight.com/report-store/hypertrophic-scar-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Hypertrophic Scar Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Hypertrophic Scar, historical and forecasted epidemiology as well as the Hypertrophic Scar market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Lung Fibrosis Market https://www.delveinsight.com/report-store/lung-fibrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Lung Fibrosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Lung Fibrosis, historical and forecasted epidemiology as well as the Lung Fibrosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Anterior Uveitis Market https://www.delveinsight.com/report-store/anterior-uveitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Anterior Uveitis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Anterior Uveitis, historical and forecasted epidemiology as well as the Anterior Uveitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

22q11.2 deletion syndrome Market https://www.delveinsight.com/report-store/22q112-deletion-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "22q11.2 Deletion Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the 22q11.2 Deletion Syndrome, historical and forecasted epidemiology as well as the 22q11.2 Deletion Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

X-Linked Retinitis Pigmentosa (XLRP) Market https://www.delveinsight.com/report-store/x-linked-retinitis-pigmentosa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "X-Linked Retinitis Pigmentosa Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the X-Linked Retinitis Pigmentosa (XLRP), historical and forecasted epidemiology as well as the X-Linked Retinitis Pigmentosa market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
www.delveinsight.com/consulting

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.